Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $30.3 which represents a decrease of $-0.45 or -1.46% from the prior close of $30.75. The stock opened at $30.79 and touched a low of ...

Decided to add this retail giant to your portfolio? Here's what you need to know before buying Amazon stock. Many, or all, of the products featured on this page are from our advertising partners ...

Shares of Royalty Pharma (RPRX) have gained 23.4% over the past four weeks to close the last trading session at $30.75, but there could still be a solid upside left in the stock if short-term price ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 14.35% ...

Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) was the target of unusually large options trading activity on Tuesday. Investors purchased 2,751 call options on the company. This represents an ...

Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) has received a consensus rating of “Buy” from the seven ratings firms that ...

TD Cowen analyst Michael Nedelcovych reiterated a Buy rating on Royalty Pharma (RPRX – Research Report) today and set a price target of ...

Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 200-day moving average, ...

Royalty Pharma plc's ( NASDAQ:RPRX) periodic dividend will be increasing on the 10th of March to $0.22, with investors receiving 4.8% more than last year's $0.21. The payment will take the dividend ...

Despite a lackluster performance from Wall Street’s major indices, 10 companies demonstrated notable resilience.

YTD Price Performance: 1.59% Average Trading Volume: 2,823,051 Technical Sentiment Consensus Rating: Buy Current Market Cap: $15.44B Find detailed analytics on RPRX stock on TipRanks’ Stock ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...